Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MyVax and Rituximab in Refractory/Progressive Follicular Lymphoma
NCT00071955Phase 2Completed
- Sponsor
- Genitope Corporation
- Start
- Mar 2003
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 2, open-label trial of MyVax in follicular lymphoma (FL) (3 arms), sponsored by Genitope Corporation. Primary endpoint: Progression-Free Survival. Started Mar 2003; status: completed.
02
Drugs
MyVax
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT00071955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00071955.